67
Participants
Start Date
September 13, 2021
Primary Completion Date
June 30, 2022
Study Completion Date
June 30, 2022
mazindol extended release
Dosed orally, once daily for up to 3 weeks
Placebo
Dosed orally, once daily for up to 4 weeks.
The Center For Sleep & Wake Disorders, Chevy Chase
Superior Clinical Research, LLC, Goldsboro
Carolinas Sleep Specialists, Concord
Advanced Respiratory and Sleep Medicine, Huntersville
Bogan Sleep Consultants, Columbia
Clinical Research Institute, Stockbridge
Treken Primary care, Atlanta
NeuroTrials Research, Atlanta
The Angel Medical Research Corporation, Miami Lakes
Sleep Medicine Specialists of South Florida, Miami
Ivetmar Medical Group, Miami
St. Francis Sleep Allergy and Lung Institute, Clearwater
Sleep Disorders Center of Alabama, Birmingham
Ohio Sleep Medicine Institute, Dublin
Intrepid Research, Cincinnati
Sleep and Attention Disorders, Sterling Heights
Neurology and Sleep Disorders Clinic, Columbia
Dharma PA d/b/a Southwest Family Medicine Associates, Dallas
Sleep Therapy & Research Center, San Antonio
Pacific Research Network, San Diego
Stanford Sleep Medicine Center, Redwood City
Hawaii Pacific Neuroscience Clinical Research Center, Honolulu
Lead Sponsor
NLS Pharmaceutics
INDUSTRY